key: cord-0757764-tvfe29no
authors: Qin, Caroline X.; Auerbach, Scott R.; Charnaya, Olga; Danziger‐Isakov, Lara A.; Ebel, Noelle H.; Feldman, Amy G.; Hsu, Evelyn K.; McAteer, John; Mohammad, Saeed; Perito, Emily R.; Thomas, Ashley M.; Chiang, Teresa P. Y.; Garonzik‐Wang, Jacqueline M.; Segev, Dorry L.; Mogul, Douglas B.
title: Antibody response to 2‐dose SARS‐CoV‐2 mRNA vaccination in pediatric solid organ transplant recipients
date: 2021-09-30
journal: Am J Transplant
DOI: 10.1111/ajt.16841
sha: 9333c7e4b038efa87ea7948846c30e3c5abba105
doc_id: 757764
cord_uid: tvfe29no

While many adult solid organ transplant recipients (SOTRs) have impaired antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, pediatric SOTRs' response has not been assessed.1-2 We report the immunogenicity and safety of BNT162b2 mRNA vaccination in pediatric SOTRs.

After approval by the Johns Hopkins University Institutional Review Board, pediatric (12-18 years) SOTRs were recruited April-August 2021 through clinic communications and social media for this prospective cohort. Samples were drawn before vaccination, two weeks after vaccine 1 (post-V1), and one month after vaccine 2 (post-V2) and were processed using the Roche Elecsys anti-SARS-CoV-2 S enzyme immunoassay for antibodies against the spike protein receptor-binding domain. 3 A positive cutoff of ≥0.8 U/ml was used. 4

All patients were included in the safety analysis (N = 57). After exclusion of patients with reported previous SARS-CoV-2 infection or history of a pre-vaccination positive antibody test (n = 5), antibody serologies from 52 patients were available for analysis. Of these 52 patients, 7 had only post-V1 serologies available, 15 had only post-V2 serologies available, and 30 had serologies for both post-V1 and post-V2. Fisher's exact test was used to compare patients who did and did not develop a positive antibody response post-V2 (n = 45). All analyses used Stata 15.1 (StataCorp).

Fifty-seven pediatric SOTRs received the BNT162b2 vaccine. 

In this observational cohort, 73.3% of pediatric SOTRs had a positive antibody response after receiving two doses of BNT162b2.

Compared to adult SOTRs with reported seroconversation rates ranging from 5% to 58.8%, 5 these findings suggest that pediatric SOTRs may be able to mount more robust immune responses to SARS-CoV-2 vaccination. Similar to adult SOTRs, shorter time from transplantation, use of multiple immunosuppressive agents, and maintenance anti-metabolite immunosuppression were associated with a negative antibody response. 1,2 Importantly, no organ rejection or other unanticipated adverse events were reported.

While this is a small convenience sample, our preliminary data, which is the first on vaccine response in pediatric SOTRs in the United States, suggest that SARS-CoV-2 vaccination is immunogenic and safe. Given the recent Food and Drug Administration emergency authorization amendment for third vaccines in immunocompromised individuals, our data may provide further evidence for the potential need of additional vaccines for SOTRs. Larger studies will be needed on vaccination safety effectiveness in immunosuppressed children and interventions to optimize response. Three patients excluded because of incomplete data. f Includes reported immunosuppression agents used at start of the study or at time of vaccine 1. Immunosuppression was not mutually exclusive, as some patients were on multiple agents. 0 patients were on everolimus or belatacept for their baseline immunosuppresion regimen prior to this study. 0 patients reported being on medications for other immune conditions including adalimumab, anakinra, baricitinib, belimumab, budesonide, certolizumab, cyclophosphamide, etanercept, hydroxychloroquine, infliximab, leflunomide, methotrexate, natalizumab, ocrelizumab, rituximab, sulfasalazine, tocilizumab, tofacitinib, and ustekinumab. g One missing (negative).

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers

SARS-CoV-2 vaccination in solid-organ transplant recipients: what the clinician needs to know